126 related articles for article (PubMed ID: 35584168)
21. Prolonging Survival in Advanced Esophageal Squamous Cell Carcinoma With Immune Checkpoint Inhibitors.
Markar SR
Gastroenterology; 2022 Aug; 163(2):527. PubMed ID: 35660032
[No Abstract] [Full Text] [Related]
22. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
24. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Qiu HB
Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.
Deng W; Chen J; Xiao Z
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):802-803. PubMed ID: 31654164
[No Abstract] [Full Text] [Related]
27. A Potential Indication for Adjuvant Therapy in Node-Negative Esophageal Squamous Cell Carcinoma.
Popoff AM
Ann Surg Oncol; 2020 Oct; 27(11):4091-4092. PubMed ID: 32691336
[No Abstract] [Full Text] [Related]
28. Polymorphism of
Yang Y; Jia J; Sun Z; Liu C; Li Z; Xiao Y; Yu J; Du F; Shi Y; Sun J; Shui J; Zhang X
Future Oncol; 2021 Jun; 17(18):2351-2363. PubMed ID: 33709789
[TBL] [Abstract][Full Text] [Related]
29. Papulopustular rosacea during nivolumab therapy of metastatic squamous cell esophageal carcinoma.
Gahoonia NK; Carrington AE; Chambers CJ; Sivamani RK
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755982
[TBL] [Abstract][Full Text] [Related]
30. Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?
van Laarhoven HW
Lancet Oncol; 2020 Jun; 21(6):743-745. PubMed ID: 32502437
[No Abstract] [Full Text] [Related]
31. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Kim JH; Ahn B; Hong SM; Jung HY; Kim DH; Choi KD; Ahn JY; Lee JH; Na HK; Kim JH; Kim YH; Kim HR; Lee HJ; Kim SB; Park SR
Cancer Res Treat; 2022 Apr; 54(2):505-516. PubMed ID: 34176250
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
Shah MA; Hofstetter WL; Kennedy EB;
J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
[No Abstract] [Full Text] [Related]
33. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
34. Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma.
Kam AE; Pappas SG; Masood A
Ann Surg Oncol; 2020 May; 27(5):1314-1315. PubMed ID: 31848823
[No Abstract] [Full Text] [Related]
35. The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.
Takegawa N; Hirabayashi T; Tanaka S; Nishikawa M; Tokuyama N; Mimura T; Kushida S; Tsumura H; Yamamoto Y; Miki I; Tsuda M
PLoS One; 2023; 18(5):e0285365. PubMed ID: 37146004
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T; Shimokawa M; Matsumoto T; Boku S; Yasuda T; Shibata N; Kurioka Y; Takatani M; Nobuhisa T; Namikawa T; Kitagawa H; Hanazaki K; Doi K; Shimada T; Tsumura T; Marusawa H; Kanaya S; Morita S; Inokuma T; Nagai H; Yasui H; Satake H
Cancer Immunol Immunother; 2023 Feb; 72(2):427-435. PubMed ID: 35927359
[TBL] [Abstract][Full Text] [Related]
37. Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
Okada M; Kato K; Cho BC; Takahashi M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Matsumura Y; Takazawa A; Kitagawa Y
Clin Cancer Res; 2022 Aug; 28(15):3277-3286. PubMed ID: 35294546
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma.
Liu G; Wang Y; Wang C; He Y; E M
Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1423-1430. PubMed ID: 33115264
[No Abstract] [Full Text] [Related]
39. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.
Ebert MP; Meindl-Beinker NM; Gutting T; Maenz M; Betge J; Schulte N; Zhan T; Weidner P; Burgermeister E; Hofheinz R; Vogel A; Angermeier S; Bolling C; de Wit M; Jakobs R; Karthaus M; Stocker G; Thuss-Patience P; Leidig T; Gaiser T; Kather JN; Haertel N
Lancet Healthy Longev; 2022 Jun; 3(6):e417-e427. PubMed ID: 36098320
[TBL] [Abstract][Full Text] [Related]
40. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
